MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: an analysis of intratumoral MET status heterogeneity and clinicopathological characteristics

Highlights • MET mutations is detected in 8.8% of triple-negative adenocarcinomas of the lung. • MET mutations is detected in 20% of pleomorphic carcinomas of the lung. • MET -mutated adenocarcinoma is characterized by older age and an acinar histology. • MET gene amplification might occur in the tu...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2017-04, Vol.106, p.131-137
Main Authors: Kwon, Dohee, Koh, Jaemoon, Kim, Sehui, Go, Heounjeong, Kim, Young A, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong-Wan, Jeon, Yoon Kyung, Chung, Doo Hyun
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adenocarcinoma - drug therapy
Adenocarcinoma - genetics
Adenocarcinoma - pathology
Adenocarcinoma - surgery
Adenocarcinoma of Lung
Adult
Aged
Aged, 80 and over
Amplification
Anaplastic Lymphoma Kinase
Cell Line, Tumor
ErbB Receptors - genetics
Exons
Female
Gene Amplification
Gene Dosage
Hematology, Oncology and Palliative Medicine
Humans
Lung
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Lung Neoplasms - surgery
Male
MET
Middle Aged
Mutation
Neoadjuvant Therapy
Pleomorphic carcinoma
Proto-Oncogene Proteins c-met - drug effects
Proto-Oncogene Proteins c-met - genetics
Proto-Oncogene Proteins c-met - metabolism
Proto-Oncogene Proteins p21(ras) - genetics
Pulmonary/Respiratory
Receptor Protein-Tyrosine Kinases - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • MET mutations is detected in 8.8% of triple-negative adenocarcinomas of the lung. • MET mutations is detected in 20% of pleomorphic carcinomas of the lung. • MET -mutated adenocarcinoma is characterized by older age and an acinar histology. • MET gene amplification might occur in the tumor cells harboring the MET mutation.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2017.02.008